Immunotherapy

Article	Citations
Alemtuzumab-Induced Red Cell Aplasia And Other Immune Cytopenias: Not So €˜Pure’	69
An Update on the Adalimumab Biosimilar Landscape Following Approval of the First High-Concentration Biosimilar	63
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study	51
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma	40
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study	40
CT-P13 Subcutaneous Infliximab in Gastroenterology and Rheumatology	38
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma	35
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia	31
Chimeric Antigen Receptor Macrophage for Glioblastoma Immunotherapy: The Way Forward	29
Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma	29
Mesenchymal Stem Cells Derived from Human Dental Follicle Modulate the Aberrant Immune Response in Atopic Dermatitis	27
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data	26
Immunotherapy for Gastric Cancer: A 2021 Update	24
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158	23
Safety and Effectiveness of the 300 IR Sublingual House Dust Mite Allergen Immunotherapy Tablet: 2-Year Interim Analysis of a Specified Drug-Use Survey	21
Subcutaneous Immunoglobulin Use in Immunoglobulin-Naive Patients with Primary Immunodeficiency: A Systematic Review	20
Treatment and Overall Survival Among Anti-PD-1-Exposed Advanced Melanoma Patients with Evidence of Disease Progression	19
Postvaccination immune-mediated hepatitis: what do we really know?	18
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas	18
Assessing Pd-L1 Status in Mrcc Treated with First-Line Immune-Based Combinations: A Meta-Analysis	16
Checkpoint Inhibitors in BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Can they Help Spare the Bladder?	16
Immune Checkpoint Inhibitors Use and Effects on Prognosis of COVID-19 Infection: A Systematic Review and Meta-Analysis	15
Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy	15
Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review	15
Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors	14

Durvalumab after Chemoradiotherapy in Patients with Stage III Non-Small-Cell Lung Cancer: Real-World Outcomes Versus Clinical Trial Results	14
Cost–Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer	13
Uveitis Associated with Cancer Immunotherapy: Long-Term Outcomes	13
What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?	12
Adherence, persistence and treatment switching in psoriasis	12
Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis	12
4-1BB Antibody Enhances Cytotoxic Activity of Natural Killer Cells Against Prostate Cancer Cells Via NKG2D Agonist Combined with IL-27	12
Anlotinib Succeeded in Rescue Therapy For Hyperprogression Induced by Immune Checkpoint Inhibitors: A Case Report	12
Cancer Immunotherapy Via Stem Cell-Derived NK Cells	12
Safety and Efficacy of Mutant Neoantigen-Specific T-Cell Treatment Combined Anti-Pd-1 Therapy in Stage Iv Solid Tumors	12
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review	11
Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics	11
SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma	11
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors	11
Efficacy of mIte Allergen Immunotherapy in Allergic Rhinitis and the Immune Synergistic Effect on Cross-Allergens	11
Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins	10
Immune Checkpoint Inhibitors in Cholangiocarcinoma	10
Deucravacitinib in Moderate-To-Severe Psoriasis	10
Liquid biopsy for guiding breast cancer immunotherapy	10
Durvalumab in Advanced Cholangiocarcinoma: Is Someone Knocking Down the Door?	10
Infection Rates and Tolerability of Three Different Immunoglobulin Administration Modalities in Patients with Primary Immunodeficiency Diseases	10
Current Immunosuppression Strategies in Pediatric Heart Transplant	10
Immune-Checkpoint Inhibitors in Renal Transplanted Patients Affected by Melanoma: A Systematic Review	10
Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma	10
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management	9
A Summertime Pause in Immunoglobulin Replacement Therapy: A Prospective Real-World Analysis	9
Poor Response to Sintilimab Plus Chemotherapy in a Pulmonary Epithelioid Hemangioendothelioma Patient: A Case Report	9
Integrase inhibitors: current protagonists in antiretroviral therapy	9
Emerging Advances in Nanomedicine for Breast Cancer Immunotherapy: Opportunities and Challenges	9
Applications and Current Challenges of Chimeric Antigen Receptor T Cells in Treating High-Grade Gliomas in Adult and Pediatric Populations	9
Immune-Related Gigantomastia: A Case Study	9
Human Growth Hormone Supplement Promotes Human Lymphohematopoietic Cell Reconstitution in Immunodeficient Mice	9
Lessons From the Diagnosis and Treatment of Severe Immune Checkpoint Inhibitor-Associated Pneumonia: A Case Report	9
Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature	9
Immune Checkpoint Inhibitor-Induced Autoimmune Encephalitis in Metastatic Squamous Cell Lung Cancer	9
Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report	8
Treatment of Plaque Psoriasis with Deucravacitinib (POETYK PSO-1 Study): A Plain Language Summary	8
TOPAZ-1: A New Standard of Care for Advanced Biliary Tract Cancers?	8
Immune Checkpoint Inhibitors in Lung Tumors with Rare Histologies and Other Thoracic Malignancies	8
Effectiveness of COVID-19 Vaccines Against Omicron Variant	8
Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib	8
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis	8
Abrocitinib for the Treatment of Atopic Dermatitis	8
Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Acute and Chronic Steroid-Refractory Gvhd Mouse Models	8
Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens	8
Ipilimumab and Nivolumab: The ‘New Kid on the Block’ in Advanced Angiosarcoma	8
Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs	8
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma	7
Intratumoral Delivery of Immune Therapy and Gene Therapy: The Next Era for Cancer Therapy	7
Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events	7

Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis	7
Late-Onset Toxicities of Monoclonal Antibodies in Cancer Patients	7
A Meta-Analysis of Application of Pd-1/Pd-L1 Inhibitor-Based Immunotherapy in Unresectable Locally Advanced Triple-Negative Breast Cancer	7
Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors	7
Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease	7
Steroid-Dependent Polyarthritis Induced by Immune Checkpoint Inhibitor Therapy Successfully Treated with Bimekizumab	7
Indirect Comparison of Pembrolizumab Monotherapy Versus Nivolumab + Ipilimumab in First-Line Metastatic Lung Cancer	7
Long-Term Response to Camrelizumab in a Pretreated Metastatic Mixed Testicular Germ-Cell Tumor Patient with Co-Mutations in DNA Damage-Repair Genes	7
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma	7
Impact of Helicobacter Pylori Infection on The Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis	7
Therapeutic Intervention of Glioma with the Novel Antineoplastic Agent T11TS: The Story so Far	7
The Effect of Low-Dose Chemotherapy on the Tumor Microenvironment and its Antitumor Activity Combined with Anti-PD-1 Antibody	6
Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis	6
Could senescent cells be the prescription for therapeutic cancer vaccines?	6
Immunotherapies for prevention and treatment of type 1 diabetes	6
Combination of Methotrexate with Oral Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Systematic Review	6
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)	6
Pathological Findings Directing Immunotherapy in Renal Cell Carcinomas	6
Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study	6
A New Perspective on The Potential Application of Ripk1 in the Treatment of Sepsis	6
A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis	6
Urothelial Carcinoma in The Era of Immune Checkpoint Inhibitors	6
Indications and Effects of Biological Agents in the Treatment of Noninfectious Uveitis	6
Pembrolizumab in an HIV-infected patient with glioblastoma	6
An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy	6
Allogeneic CAR-T cells for cancer immunotherapy	6
Fractional Exhaled Nitric Oxide in Checkpoint Inhibitor Pneumonitis: A Case Report and Literature Review	6
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer	6
Therapeutic Cancer Vaccine Therapy for Acute Myeloid Leukemia	6
Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy	6
Neoadjuvant Immunochemotherapy in the Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: A Systematic Review	6
Cutaneous Metastases at the Sites of Pembrolizumab-Induced Bullous Pemphigoid Lesions in a Patient with Melanoma	6
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?	6
Ocular Toxicities in Chimeric Antigen Receptor T-Cell Therapy: A Real-World Study Leveraging FAERS Database	6
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab	6
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China	6
The Development of Litifilimab (BIIB 059) for Cutaneous and Systemic Lupus Erythematosus	6
Safety and Effectiveness of a 300 IR House Dust Mite Sublingual Tablet: Descriptive 4-Year Final Analysis of a Post-Marketing Surveillance in Japan	6
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases	6
Real-World Study: Drug Reduction in Children With Allergic Rhinitis and Asthma Receiving Immunotherapy	5
Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review	5
Amalgamation of Nanotechnology with Chicken IgY to Enrich Therapeutic and Diagnostic Applications: A Systematic Review	5
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study	5
Treatment of EAE Mice with Treg, G-MDSC and IL-2: a New Insight into Cell Therapy for Multiple Sclerosis	5
Peripheral Blood Eosinophil Count is Associated with Response to Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer	5
Tsunami of Immunotherapies in the Management of Esophageal Cancer	5
Infrequent Liver Injury from Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma	5
Treatment of Children with Primary Immunodeficiencies with a Subcutaneous Immunoglobulin 16.5% (Cutaquig ®  [Octanorm])	5
ICAM2 is Related to Good Prognosis in Dendritic Cell Immunotherapy for Cancer	5
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations	5
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma	5
Nivolumab-Induced Systemic Capillary Leak Syndrome as an Ultra Rare Life-Threatening Phenomenon of Late Toxicity and Intravenous Immunoglobulin Efficacy	5
Pembrolizumab: A New Standard of Care in Metastatic Colorectal Cancer	5
Summary of Certolizumab Pegol in Psoriasis Including Structural Features, Pharmacokinetics and Treatment	5
Peptide–MHC Complexes: Dressing up to Manipulate T Cells Against Autoimmunity and Cancer	5
Anaphylaxis to Tocilizumab in Patients with Rheumatic Disease	5
An Unusual Case of Immune-Related Gastritis in One Patient Receiving Toripalimab Therapy	5
Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary	5
Pegcetacoplan Treatment for Geographic Atrophy Due to Age-Related Macular Degeneration: A Plain Language Summary of the FILLY Study	5
Abscopal Effect and Resistance Reversion in Nivolumab-Treated Non-Small-Cell Lung Cancer Undergoing Palliative Radiotherapy: A Case Report	5
A CD123-Specific Chimeric Antigen Receptor Augments Anti-Acute Myeloid Leukemia Activity of Vγ9Vδ2 T Cells	5
The Use of Dostarlimab, a Safe and Efficient Monotherapy in Msi-H Rectal Cancer Patients, an Alternative to Surgery	5
A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement	5
Radiation and Resolve: Unlocking the Synergistic Potential of Radioimmunotherapy in Advanced Lung Cancer Management	5
Pd-1/L1 Inhibitors May Increase the Risk of Pericardial Disease in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis and Systematic Review	5
Moving Beyond Single-Agent Checkpoint Inhibition in Biliary Tract Cancers: What is the Next Frontier?	5
Targeting the Tumor Microenvironment of Ewing Sarcoma	5
Oncolytic Viruses in Lung Cancer Treatment: A Review Article	5
Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates	5
Chemotherapy or Chemo-Immunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer: A Meta-Analysis	5
A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents	5
Immune Checkpoint Inhibitors for Advanced or Metastatic Basal Cell Carcinoma: How much Evidence do we Need?	4
Metastatic Gastric Cancer: Synergizing and Sequencing Targeted Therapy with First-Line Immunotherapy	4
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis	4
Overcoming Immune-Resistance in Laryngeal Cancer: A Case Report of the Abscopal Effect and Nivolumab Beyond Progression	4
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice	4
Immune Checkpoint Inhibitors and Combinations with Other Agents in Cholangiocarcinoma	4
Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors	4
Bimekizumab for The Treatment of Psoriasis	4
Current Landscape of Immunotherapy Trials in Locally Advanced and High-Risk Head and Neck Cancer	4

Mirna Profiles Change During Grass Pollen Immunotherapy Irrespective of Clinical Outcome	4
Satisfaction, Qol and adherence of patients allergic to dust mites and/or pollens undergoing sublingual immunotherapy	4
Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation	4
Severe Pseudomembranous Keratoconjunctivitis with Deterioration of Eyesight Induced by Immune Checkpoint Inhibitors	4
Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults	4
Late-onset recurrent immune checkpoint inhibitor-related pneumonitis after cessation of pembrolizumab: a case report	4
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives	4
Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance?	4
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy	4
Cemiplimab-Induced Cytokine-Release Syndrome: Second Case Reported and Review of The Literature	4
Thyroid Function Impairment after Chemo-Immunotherapy for Advanced Nsclc: A Single Institutional Retrospective Report	4
Tezepelumab for the Treatment of Severe Asthma: A Plain Language Summary of the PATHWAY and NAVIGATOR Studies	4
Cost–Effectiveness Analysis of Nivolumab Plus Cabozantinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma	4
Immunotherapy in Atopic Dermatitis	4
TYK2 as a Therapeutic Target in the Treatment of Autoimmune and Inflammatory Diseases	4
Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event	4
Imaging-calculated splenic volume is associated with response in melanoma patients treated with immunotherapy	4
Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease	4
Multicenter Real-World Experience with Epinephrine 0.5 mg Dosing for Anaphylaxis with Allergen Immunotherapy	4
Efficacy of Long-Term Repeated Rituximab Treatment in Refractory Phospholipase A2 Receptor-Antibody-Related Membranous Nephropathy	4
Successful Use of Secukinumab in Two Melanoma Patients with Immune Checkpoint Inhibitor-Induced Inflammatory Arthropathy	4
Effect of Neoadjuvant Therapy on Tumor Tissue PD-L1 and VISTA Expression Levels in Non-Small-Cell Lung Cancer	4
Surrogate end Points for Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors	3
Safety of Subcutaneous and Sublingual Immunotherapy with Allergoids in Children: A Real-Life Pharmacovigilance Study	3
Durable Response after Immunotherapy Discontinuation for Delayed and Severe Immune-related Adverse Event: A Case Report	3
FHL1 As a Novel Prognostic Biomarker and Correlation with Immune Infiltration Levels in Lung Adenocarcinoma	3
Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database	3
Immune Checkpoint Inhibitor-Related Chronic Pneumonitis: A Case Report and Literature Review	3
Combination of Bevacizumab and Dual Immunotherapy for Extensive-Disease Small-Cell Lung Cancer: A Case Report	3
Outcomes for Pembrolizumab Stratified by Pemetrexed Maintenance Post Pembrolizumab–Platinum–Pemetrexed Induction in Metastatic Non-Small-Cell Lung Cancer	3
Enhanced Binding at Fever Temperatures of HER2 in Complex with Trastuzumab and Pertuzumab	3
The Evolution of Biliary Tract Cancer: Introducing a Special Focus Issue from Immunotherapy	3
Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient	3
Immunology of Osteoporosis: Relevance of Inflammatory Targets for the Development of Novel Interventions	3
The role of nemolizumab in the treatment of atopic dermatitis for the adult population	3
Plain Language Summary of the VOLTAIRE-RA in Patients with Moderate-To-Severe Rheumatoid Arthritis	3
Failure of immune checkpoint inhibitors for microsatellite instability-positive pancreatic adenocarcinoma with atypical pattern of short tandem repeat mutation	3
Alpha/beta-defensins influence on the humoral immunity and complications in cancer of the oral cavity and oropharynx	3
Cost–effectiveness of Adjuvant Atezolizumab for Patients with Stage II–IIIA PD-L1+ Non-Small-Cell Lung Cancer	3
Management of PD-1/PD-L1 Blockade Immune-Related Skin Toxicities: Perspectives and Issues	3
Sintilimab Plus Sorafenib: A novel Regimen for Hepatocellular Carcinoma	3
Pembrolizumab-Induced Follicular Eruption and Response to Isotretinoin	3
A Review of Phase Iii Clinical Trials of Us Fda-Approved Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyposis	3
Comparing how Well Abrocitinib and Dupilumab Treat Atopic Dermatitis Signs and Symptoms: A Plain Language Summary	3
Poor survival of metastatic cancer patients hospitalized due to immune checkpoint inhibitor-related adverse events	3
Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics	3
Efficacy of Pd-1/Pd-L1 Inhibitors in Advanced Gastroesophageal Cancer Based on Characteristics: A Meta-Analysis	3
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study	3
Anti-PD-1 and Regorafenib Induce Severe Multisystem Adverse Events in Microsatellite Stability Metastatic Colorectal Cancer: A Case Report	3
Treatment and Prognostic Implications of Strong PD-L1 Expression in Primary Hepatic Sarcomatoid Carcinoma	3
CAR-T cells for H3K27-altered diffuse midline gliomas: where do we stand?	3
Immunotherapy for Cholangiocarcinoma: a 2021 Update	3
Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis in a Patient with Chronic Lymphocytic Leukemia	3
Immunotherapy for Head and Neck Cancer: Where do We Go from Here?	3
The role of dupilumab in the treatment of eosinophilic esophagitis	3
Complete Response and Survival Outcomes in Patients with Advanced Cancer on Immune Checkpoint Inhibitors	3
Etrasimod for the Treatment of Ulcerative Colitis	3
Safety and Effectiveness of Intravenous Ct-P13 in Inflammatory Arthritis: Post-Marketing Surveillance Study in Thailand	3
Welcome to The 14th Volume of Immunotherapy	3
Targeting CD47 Enhanced the Antitumor Immunity of PD-L1 Blockade in B-Cell Lymphoma	3
Clinical Outcomes of Immune Checkpoint Inhibitor Diabetes Mellitus at a Comprehensive Cancer Center	3
Combined Application of Bevacizumab and Pd-1 Blockade Displays Durable Treatment Effects by Increasing the Infiltration And Cytotoxic Function of Cd8 + T Cells in Lu	3
Systemic Immune–Inflammation Index Predicts Prognosis of Cancer Immunotherapy: Systemic Review and Meta-Analysis	3
Interpatient Variability in Mesothelin Expression Necessitates its Evaluation Before Gastric Cancer Immunotherapy	3
Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases	3
Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe	3
Immunoregulatory Effects of Dental Mesenchymal Stem Cells on T and B Lymphocyte Responses in Primary Sjögren's Syndrome	3
Autologous Enzyme-Linked Immunosorbent Facilitated Antigen Binding Detects Ige-Blocking Activity Based on Direct Competition between Allergen-specific IgE and Non-IgE	3
Efficacy of Therapies Targeting TGF-β in Solid Tumors: a Systematic Review and Meta-Analysis of Clinical Trials	3
A Common Approach for Fighting Tuberculosis and Leprosy: Controlling Endoplasmic Reticulum Stress in Myeloid-derived Suppressor Cells	3
Is There a Role for Immune Checkpoint Inhibitors in Chordoma?	3
Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy	3
Reversing Chemokine/Chemokine Receptor Mismatch to Enhance the Antitumor Efficacy of CAR-T Cells	3
Real-World Study of PD-L1 Testing Patterns and Treatment Distribution in Patients with Metastatic Non-Small-Cell Lung Cancer in Israel	3
Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis	2
Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis	2
Anti-PD-1 Treatment-Induced Immediate Central Diabetes Insipidus: A Case Report	2
Clinical Course and Management of Pembrolizumab-Associated Isolated Adrenocorticotrophic Hormone Deficiency: A New Case and Literature Review	2
Use of Upadacitinib in the Treatment of Psoriatic Arthritis	2
Immunotherapy with γδ T-cells: the future is there	2
Volume Increase of Spleen in Melanoma Patients Undergoing Immune Checkpoint Blockade	2
Hyperprogressive Disease in Leiomyosarcoma: A Threat to the Use of Single-Agent Anti-Pd-(L)1 Therapy?	2
Neoadjuvant Immunotherapy Plus Chemotherapy and Adjuvant Targeted Therapy in ALK -Positive Non-Small-Cell Lung Cancer	2
Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe	2
Development of Hepatitis Triggered by SARS-CoV-2 Vaccination in Patient with Cancer During Immunotherapy: A Case Report	2
Fatal rhabdomyolysis and fulminant myocarditis with malignant arrhythmias after one dose of ipilimumab and nivolumab	2
Toxic Epidermal Necrolysis Associated with Chemoimmunotherapy For Lymphoma: Case Report and Literature Review	2
Cost–effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer	2
Toripalimab and Fruquintinib Therapy for Colorectal Cancer after Failed Multiline Chemotherapies: A Case Report	2
Health and Economic Impact of Subcutaneous Allergen Immunotherapy in Patients with Pollen-Induced Allergic Rhinoconjunctivitis: Real-Word Evidence from the Czech Republic	2
Tocilizumab in Grade 4 Hepatitis Secondary to Immune Checkpoint Inhibitor: A Case Report and Review of the Literature	2
Immune checkpoint inhibitors in gynecological cancers: a narrative review on the practice-changing trials	2
Hematological Prognosticators in Metastatic Renal Cell Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis	2
Impact of immune-related adverse events on survival among patients with head-and-neck squamous cell carcinoma	2
An Assessment of Extended Pembrolizumab Dosing in Advanced Non-Small-Cell Lung Cancer in the Covid-19 Pandemic	2